The sky-high costs to Medicare for prescriptions of the MS medication H.P. Acthar Gel,  as reported in Multiple Sclerosis News Today were highlighted at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in…

Celgene Corporation announced the results from an extension study of the RADIANCE Phase 2 clinical trial evaluating ozanimod in patients with relapsing multiple sclerosis (MS). The results were also presented at the recent Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 in New Orleans, Louisiana. Ozanimod is a small…

Dr. Andrew Goodman of the University of Rochester discussed the latest research and perspectives on stem cell strategies for people with multiple sclerosis (MS), saying in a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 that such therapies, while promising, are not yet ready for widespread clinical use. New therapies…

Researchers at Johns Hopkins University in Baltimore presented key findings today, Feb. 19, concerning the presence of contrast-enhancing lesions in later stages in the relapsing-remitting experimental autoimmune encephalitis (EAE) model. The presentation was made at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, which is ongoing through…

Dr. Timothy Coetzee from the National Multiple Sclerosis Society will present an overview of the objectives and achievements of the International Progressive MS Alliance (PMSA), an organization dedicated to facilitating and funding research on progressive multiple sclerosis (MS), a form of MS especially lacking effective therapeutic options. Coetzee…

Dr. Daniel S. Reich with Johns Hopkins University  is giving an oral talk on “MRI as an Outcome Measure in Progressive Multiple Sclerosis” at Friday’s ACTRIMS Forum 2016. This year’s meeting focuses on progressive MS, and runs through Saturday, Feb. 20, in New Orleans. Magnetic resonance imaging (MRI) has been the…

Dr. Wayne Moore, from the University of British Columbia and the Vancouver General Hospital, will present an overview and analysis of the major histology and pathology aspects that characterize and differentiate relapsing-remitting multiple sclerosis (RRMS) and progressive forms of the disease, primary progressive MS (PPMS) and secondary progressive MS (SPMS).

At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18–20 in New Orleans, LA, researchers have gathered to discuss “Progressive MS: Bench to Bedside and Back,” the meeting’s theme. Secondary progressive multiple sclerosis (SPMS) is one of four types of MS, and is…

Researchers from the University of Tennessee Health Science Center plan to present the results of a study investigating the contribution of specific antibodies to the neurodegeneration and neuronal dysfunction observed in multiple sclerosis (MS). The study’s results are to be reported today, Feb. 18, at the Americas Committee for Treatment and Research…

Brian M. Sandroff from the Kessler Foundation and Robert W. Mot with the University of Illinois will present the results of a study on the effects of exercise in patients with multiple sclerosis (MS) today, Feb.18, at the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS)…

Scientists from the Neuroimmunological Diseases Unit at the National Institutes of Health (NIH) will present results of a study investigating several biomarkers that might lead to a more sensitive and accurate diagnostic test of central nervous system (CNS) inflammation, a key aspect of progressive multiple sclerosis (MS). The data is being reported today, Feb.18, at the…

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 starts today, Feb. 18, in New Orleans, Louisiana, and runs through Saturday, Feb. 20. The opening day’s Session 1, titled “Emerging Concepts in MS,” places special focus on cutting-edge studies on the pathogenic mechanisms in multiple sclerosis (MS), new measures of…

Anavex Life Sciences, a biopharmaceutical company focused on the development of new therapies for neurodegenerative and central nervous system (CNS) diseases, among others, recently announced the presentation of preclinical data for one of its lead drug candidates, ANAVEX2-73, as a multiple sclerosis (MS) treatment. The preclinical study’s lead investigator, Dr.

Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment for primary progressive multiple sclerosis (PPMS), Breakthrough Therapy Designation based on positive Phase 3 clinical trial results showing that ocrelizumab significantly reduced disability progression and other disease activity markers compared to placebo. The FDA designation is…

The first standalone forum held by the Madison, Wisconsin-based Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) gets underway  Thursday, Feb. 18, and runs through Feb. 20 in New Orleans, Louisiana. The forum, “Progressive MS: From Bench to Bedside and Back,” is at the Hyatt Regency New Orleans at…

EMD Serono, the North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over Rebif (interferon beta-1a) in the United States. Rebif  is a treatment for relapsing forms of multiple sclerosis (MS). Rebif, an approved drug, is used to decrease the frequency of MS relapses and delay the occurrence of…

Dr. Jerry S. Wolinsky of the University of Texas in Houston, will give the first Kenneth P. Johnson Memorial Lecture at the opening day of the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 in New Orleans, focusing on distinctions between relapsing and progressive disease forms. ACTRIMS…

Biopharmaceutical company Receptos, Inc. announced that they will review data from the phase 2 portion of the RADIANCE trial, the company’s phase 2 / 3 study testing RPC1063 in the treatment of Relapsing Multiple Sclerosis (RMS). The data is being presented at the largest meeting dedicated to multiple sclerosis…

Just yesterday, the President of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Suhayl Dhib-Jalbut, publicly announced the details of this year’s MSBoston2014 conference, in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). According to Dhib-Jalbut — who is also the…